A Comparative Study on Different Approaches of COVID-19 Vaccines

Md.Ashikur Rahman, Riaz Mahamud Chayon, Abdul Aziz, Fatema Tuj Johora Faria, Md. Aminul Islam and Md Rashedur Rahman
Additional contact information
Md.Ashikur Rahman: Primeasia University, Bangladesh
Riaz Mahamud Chayon: Primeasia University, Bangladesh
Abdul Aziz: Primeasia University, Bangladesh
Fatema Tuj Johora Faria: Primeasia University, Bangladesh
Md. Aminul Islam: Primeasia University, Bangladesh
Md Rashedur Rahman: Primeasia University, Bangladesh

European Journal of Pharmaceutical Research, 2023, vol. 3, issue 4, 1-13

Abstract: Worldwide recorded 324 million human infected coronavirus patients and a mortality rate of over 5.53 million till now. In this situation coronavirus type-2 has suddenly arisen as a global problem. It impacts all humans directly via disease and death and indirectly by isolation creates a tremendous financial and psychological barrier. It remains the most feasible method so far but is untenable beyond a lengthy period. At this time vaccine development is the most helpful strategy for controlling emerging virus strains. Pfizer/BioNTech (Ribonucleic acid vaccine), Johnson and Johnson, Novavax (UK), AstraZeneca, Sinovac (China), Moderna (Ribonucleic acid), CanSinoBio, and Covishield (India) etc. are among the firms involved in the continuing vaccination program, which is taking place all over the world. This assessment covers all aspects of COVID-19 and concentrates on the following approaches. Besides AI systems, advanced drug delivery systems (nanotechnology) and a trained immunity vaccination method are being used to advance the COVID-19 vaccine development cycle. We give a glimpse of a comparative evaluation of global vaccination approaches, efficacy, adverse effects, worldwide reached vaccination, a general review of clinical trials coronavirus disease-2019 vaccines also vaccine effectiveness against novel coronavirus variants based on real-world data. Also, variants considered is the influence of disquieting variants and under of interest.

Keywords: COVID-19; Nanotechnology; Vaccine approaches; Variants (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/pharma/article/view/758 Abstract page (text/html)
https://eu-opensci.org/index.php/pharma/article/download/758/317 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:pharma:v:3:y:2023:i:4:id:758

DOI: 10.24018/ejpharma.2023.3.4.58

Access Statistics for this article

More articles in European Journal of Pharmaceutical Research from European Open Science Publishing
Bibliographic data for series maintained by Support Team ().